Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2015', provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview 9
Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis 10
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Development by Companies 11
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Investigation by Universities/Institutes 13
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Development by Companies 17
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Investigation by Universities/Institutes 19
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development 20
Ahn-Gook Pharmaceutical Co., Ltd. 20
aRigen Pharmaceuticals, Inc. 21
Cempra, Inc. 22
Daewoong Pharmaceutical Co., Ltd. 23
Eisai Co., Ltd. 24
Ironwood Pharmaceuticals, Inc. 25
Johnson & Johnson 26
Ono Pharmaceutical Co., Ltd. 27
RaQualia Pharma Inc. 28
Rottapharm SpA 29
Shire Plc 30
Sucampo Pharmaceuticals, Inc. 31
Vecta Ltd. 32
Wockhardt Limited 33
Yuhan Corporation 34
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
ARH-1029 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
cobiprostone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DWJ-1367 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
E-3710 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
esomeprazole magnesium - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
itriglumide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IW-3718 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
JNJ-26070109 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
omeprazole - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ONO-8539 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pantoprazole - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
RQ-00000004 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
RQ-00000010 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
RQ-00000774 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Inhibit Proton Pump for Gastrointestinal Disorders - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SSP-002358 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
tenatoprazole - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Vaccine to Target Gastrin for Gastrointestinal Cancers - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
YH-4808 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Recent Pipeline Updates 67
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects 71
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products 74
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones 77
Featured News & Press Releases 77
Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease 77
Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision 77
Mar 29, 2011: RaQualia Pharma Announces Successful Results From Phase I Study Of Acid Pump Antagonist 78
Apr 01, 2010: Santarus Announces Launch of ZEGERID OTC by Schering-Plough Consumer HealthCare 78
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 79
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 80
Dec 22, 2009: Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC 80
Dec 05, 2009: Santarus Receives FDA Approval for Immediate-Release Omeprazole 81
Dec 01, 2009: Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC 81
Oct 26, 2009: Santarus To Present Positive Data From Two Investigator-Initiated Studies With ZEGERID At ACG 2009 Meeting 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2015 9
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 20
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by aRigen Pharmaceuticals, Inc., H1 2015 21
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra, Inc., H1 2015 22
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 23
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co., Ltd., H1 2015 24
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 25
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Johnson & Johnson, H1 2015 26
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 27
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc., H1 2015 28
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Rottapharm SpA, H1 2015 29
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Shire Plc, H1 2015 30
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 31
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Vecta Ltd., H1 2015 32
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Limited, H1 2015 33
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuhan Corporation, H1 2015 34
Assessment by Monotherapy Products, H1 2015 35
Number of Products by Stage and Target, H1 2015 37
Number of Products by Stage and Mechanism of Action, H1 2015 39
Number of Products by Stage and Route of Administration, H1 2015 41
Number of Products by Stage and Molecule Type, H1 2015 43
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics - Recent Pipeline Updates, H1 2015 67
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2015 71
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..1), H1 2015 72
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..2), H1 2015 73
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H1 2015 74
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..1), H1 2015 75
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..2), H1 2015 76